|
Neurodegeneration Due To Cerebral Folate Transport Deficiency
|
0.790 |
Biomarker
|
phenotype |
CTD_human |
|
|
|
|
Seizures
|
0.400 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Intellectual Disability
|
0.400 |
Biomarker
|
group |
HPO |
|
|
|
|
Developmental regression
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Nerve Degeneration
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Epileptic encephalopathy
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Neurodegeneration Due To Cerebral Folate Transport Deficiency
|
0.790 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Adjusting risk factors in spontaneous abortion by multiple logistic regression.
|
2044715 |
1991 |
|
ovarian neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Folate-binding protein is a marker for ovarian cancer.
|
1717147 |
1991 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Folate-binding protein is a marker for ovarian cancer.
|
1717147 |
1991 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Folate-binding protein is a marker for ovarian cancer.
|
1717147 |
1991 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
This molecule is a high affinity folate binding protein (FBP) and a potential marker for ovarian carcinoma.
|
8242637 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth analysis revealed that FBP-transfected NIH/3T3 cells like IGROV1 maintained their growth rate after 10 days of culture in medium containing physiological or low folate concentration, and tumors arising after transplanting FBP-tNIH/3T3 cells in nude mice were 3-fold heavier than those arising after transplantation of non-FBP-expressing NIH/3T3 cells.
|
8242637 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, high affinity folate receptor (FOLR1), which maps to 11q13.3-13.5, is expressed at an elevated level on the surface of over 80% of nonmucinous epithelial ovarian cancers.
|
8094291 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This molecule is a high affinity folate binding protein (FBP) and a potential marker for ovarian carcinoma.
|
8242637 |
1993 |
|
Ovarian Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This molecule is a high affinity folate binding protein (FBP) and a potential marker for ovarian carcinoma.
|
8242637 |
1993 |
|
Nasopharyngeal carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Folate-binding protein (FBP), a high-affinity folate receptor, is responsible for cellular accumulation of folate and folate analogs such as methotrexate in human KB (nasopharyngeal carcinoma) cells.
|
8328990 |
1993 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Amplification using FBP exon-specific primers with a YAC contig from this region of chromosome 9 further refined the placement of FBP genomic sequences to an approximately 1.7-cM region flanked by D9S280 and D9S287, near the gene for Fanconi anemia group C. Precise localization of the FBP gene enabled evaluation of FBP as a candidate gene for maturity-onset diabetes of the young (MODY) and non-insulin-dependent diabetes (NIDDM) in both Caucasian and African-American families, using the highly informative markers D9S287 and D9S176.
|
8530070 |
1995 |
|
Maturity onset diabetes mellitus in young
|
0.010 |
Biomarker
|
disease |
BEFREE |
Amplification using FBP exon-specific primers with a YAC contig from this region of chromosome 9 further refined the placement of FBP genomic sequences to an approximately 1.7-cM region flanked by D9S280 and D9S287, near the gene for Fanconi anemia group C. Precise localization of the FBP gene enabled evaluation of FBP as a candidate gene for maturity-onset diabetes of the young (MODY) and non-insulin-dependent diabetes (NIDDM) in both Caucasian and African-American families, using the highly informative markers D9S287 and D9S176.
|
8530070 |
1995 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, the data suggest the possible predictive value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity.
|
9218736 |
1997 |
|
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of folate binding protein in ovarian cancers.
|
9133455 |
1997 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, the data suggest the possible predictive value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity.
|
9218736 |
1997 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using the monoclonal antibody (MAb) MOv 18 and cytofluorimetric analysis, we investigated FBP expression in frozen neoplastic tissues from 136 patients diagnosed with epithelial ovarian cancer.
|
9133455 |
1997 |
|
Epithelial ovarian cancer
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Using the monoclonal antibody (MAb) MOv 18 and cytofluorimetric analysis, we investigated FBP expression in frozen neoplastic tissues from 136 patients diagnosed with epithelial ovarian cancer.
|
9133455 |
1997 |
|
Ovarian Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Together, the data suggest the possible predictive value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity.
|
9218736 |
1997 |
|
Neural Tube Defects
|
0.400 |
GeneticVariation
|
group |
BEFREE |
It is unlikely that the beneficial effects of maternal folate supplementation in preventing NTDs acts through a mechanism involving pharmacological correction of a variant form of folate receptor alpha.
|
9545095 |
1998 |